Hints and tips:
...Even before striking the deal for Allergan, AbbVie had spent $21bn on biopharmaceutical company Pharmacyclics in 2015 in a bid to bolster its drug pipeline....
...It spent $21bn on Pharmacyclics in 2015, and then bought Stemcentrix for just under $10bn. The rise of Allergan, meanwhile, was masterminded by Mr Saunders....
...Target: Pharmacyclics Inc | Acquirer: AbbVie Deal value $21bn | Premium 61% No auction was more hotly contested than that of Pharmacyclics, which made a single drug, Imbruvica, for blood cancer....
...Last year it lost out in the race to buy Pharmacyclics, the maker of a best-selling drug for a type of blood cancer, which was eventually taken over by AbbVie for $21bn....
...The purchase of Medivation will be one of its biggest deals in the oncology field, after it lost in the race to buy Pharmacyclics last year, which was eventually taken over by AbbVie for $21bn....
...They compared the biotech group to Pharmacyclics, another cancer company that was bought by AbbVie for $21bn last year following a bitterly fought three-way auction....
...takeovers, including Actavis’s $21bn debt offering to fund its buyout of Botox maker Allergan; AT&T’s $17.5bn issuance for its takeover of DirecTV; and AbbVie’s $16.7bn deal to finance its acquisition of Pharmacyclics...
...In March 2015, he fought off stiff competition from Johnson & Johnson and Pfizer to seal the $21bn purchase of Pharmacyclics, the maker of a blockbuster drug for blood cancers....
...In March 2015, he fought off stiff competition from Johnson & Johnson and Pfizer to acquire Pharmacyclics, the maker of a blockbuster drug for blood cancers, for $21bn....
...Acerta is a US-Dutch biotech company developing a promising blood cancer drug that would, if it reaches market, be a direct challenger to the Imbruvica treatment which prompted AbbVie to buy Pharmacyclics...
...J&J tried to buy Pharmacyclics, the maker of a blockbuster blood cancer drug, in March last year, but lost out to AbbVie, which bought the company for about $21bn....
...Analysts said speculation about a $5bn valuation for Acerta sounded attractive compared with the $21bn paid by AbbVie to buy Pharmacyclics in March — giving it a half share in Imbruvica alongside co-owner...
...Imbruvica, the cancer drug that J&J sells in partnership with Pharmacyclics, also did well, with its share of sales jumping from $42m a year earlier to $154m....
...AbbVie’s $21bn swoop for Pharmacyclics was the biggest in a wave of bolt-on biotech acquisitions to reinforce innovation....
...J&J has a longstanding partnership with Pharmacyclics and receives a share of sales of Imbruvica, its top selling drug....
...J&J has a partnership with Pharmacyclics in the US....
...Robert Duggan, the 70-year-old chief executive of Pharmacyclics, has had a very good last 12 months....
...Pharmacyclics has rights to half of the US profits from Imbruvica; J&J gets the other half, along with the profits from the rest of the world....
...Pharmacyclics decided to put itself up for sale in part because the board was concerned about who would succeed Mr Duggan, aged 70, as chief executive....
...AbbVie, for example, paid $21bn for Pharmacyclics this year, largely to acquire a single blood cancer treatment. Their shareholders have become addicted to mergers....
...Why was Pharmacyclics such a prized asset?...
Yield-hunting investors have many options beyond Greek bonds
...J&J has had a partnership with Pharmacyclics since 2011, and as late as Wednesday evening it was confident that it would win one of the most competitive bidding wars for years....
...“The acquisition of Pharmacyclics is a strategically compelling opportunity....
...A good example of a research-led deal is AbbVie’s $21bn takeover of the biotech firm Pharmacyclics. The move gives the US drugmaker access to an exciting new blood cancer compound....
International Edition